Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | LITAF | Q99732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198589 | 0.84 | KDM4E (0.47) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL3193789 | 0.79 | PTPN1 (0.51) | MEN1KMT2ASMN1; SMN2TNFLITAF | |
| SCHEMBL3196801 | 0.79 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL3198134 | 0.78 | KDM4E (0.43) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL17431348 | 0.75 | KDM4E (0.69) | KMT2AKDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL3190687 | 0.73 | KDM4E (0.41) | MEN1KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL3189288 | 0.73 | KMT2A (0.44) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL4118472 | 0.73 | KDM4E (0.42) | KMT2AKDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL4132117 | 0.72 | GAA (0.48) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL4120881 | 0.72 | GAA (0.47) | MEN1KMT2AKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674822-B2 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | PTPA, PTPRCAP, PTPRC | MEN1 4743/4885KMT2A 3165/4885KDM4E 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.